ArticleLangenbeck's archives of surgery2026
Prognosis of adenosquamous carcinoma of the pancreas.
Article in Langenbeck's archives of surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePancreatic adenosquamous carcinoma (PASC) is a rare malignant pancreatic tumor, defined as a pancreatic tumor containing at least 30% squamous cell carcinoma component. Most previous publications have reported a poor prognosis for patients with PASC, but data remain scant including clinicopathological features and treatment. This study aimed to characterize the clinicopathological features and to assess the survival of patients with PASC.
methodsA single center retrospective cohort study at the Lausanne University Hospital (CHUV) was performed. Patients pathologically diagnosed with PASC from January 1, 2010, to December 31, 2023, were included. Overall survival (OS) and disease-free survival (DFS) were calculated using the Kaplan-Meier methods and log-rank test was used for comparisons.
resultsA total of 12 patients were histopathologically diagnosed with PASC. Median age at diagnosis was 67.5 years (IQR 59-75.5). Most patients were men (8/12). Eight patients underwent resection and 4 palliative chemotherapy or best supportive care. Six out of 8 patients underwent pancreatoduodenectomy. Median tumor size on pathological analysis was 4.8 cm (IQR 3.4–5.8). Median OS of the entire cohort was 9.2 months (95% CI 2.1–23.4). Median OS from time of diagnosis of patients with and without resection of PASC were 10.2 months (95% CI 2.4–24.1) vs. 8.8 months (95% CI 1.2–11.3, p = 0.23). Median DFS was 2.8 months (95% CI 1.5–23.4) for patients with resection.
conclusionsPatients with PASC had a very poor prognosis in this cohort. All patients who were not operated died before a year of the diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.